Rapid Micro Biosystems (RPID) Total Debt (2020 - 2026)

Rapid Micro Biosystems (RPID) reported Total Debt of $19.1 million for Q1 2026, up 0.8% sequentially from $18.9 million in Q4 2025.

Rapid Micro Biosystems (RPID) Total Debt (2020 - 2026) Analysis & Trends

Rapid Micro Biosystems (RPID) has 4 years of Total Debt data on file, last reported at $19.1 million in Q1 2026.

For the quarter ending Q1 2026, Total Debt changed N/A year-over-year to $19.1 million; the trailing twelve-month figure through Mar 2026 stood at $19.1 million (changed N/A YoY), and the FY2025 full-year result was $18.9 million, changed N/A from the prior year.
Total Debt grew to $19.1 million in Q1 2026, from $18.9 million in the prior quarter.
In the past five years, Total Debt ranged from a high of $19.1 million in Q1 2026 to a low of $18.8 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	34.05 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	14.72 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	27.96 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	11.03 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	598.50 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	9.48 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	10.14 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	3.18 Bn
10	Rapid Micro Biosystems	90.41 Mn	80.98 Mn	371,000.00	19.05 Mn

Download Data